Muscle Spasm – Pipeline Review, H2 2011 by GlobalMarketsDirect

VIEWS: 5 PAGES: 29

More Info
									Muscle Spasm – Pipeline Review, H2 2011




                     Muscle Spasm – Pipeline Review, H2 2011


                                                                                          Reference Code: GMDHC1609IDB
                                                                                          Publication Date: December 2011




Muscle Spasm – Pipeline Review, H2 2011                                                   GMDHC1609IDB / Pub December 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                            Page(1)
Muscle Spasm – Pipeline Review, H2 2011




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 3
    List of Figures ................................................................................................................................................................................ 4
Introduction......................................................................................................................................................................................... 5
    Global Markets Direct Report Coverage ........................................................................................................................................ 5
Muscle Spasm Overview .................................................................................................................................................................... 6
Therapeutics Development................................................................................................................................................................. 7
    An Overview of Pipeline Products for Muscle Spasm .................................................................................................................... 7
Muscle Spasm Therapeutics under Development by Companies ...................................................................................................... 9
Late Stage Products ......................................................................................................................................................................... 10
    Comparative Analysis .................................................................................................................................................................. 10
Mid Clinical Stage Products.............................................................................................................................................................. 11
    Comparative Analysis .................................................................................................................................................................. 11
Early Clinical Stage Products ........................................................................................................................................................... 12
    Comparative Analysis .................................................................................................................................................................. 12
Pre-Clinical Stage Products.............................................................................................................................................................. 13
    Comparative Analysis .................................................................................................................................................................. 13
Muscle Spasm Therapeutics – Products under Development by Companies .................................................................................. 14
Companies Involved in Muscle Spasm Therapeutics Development ................................................................................................. 15
    Eisai Co., Ltd. .............................................................................................................................................................................. 15
    Sun Pharmaceutical Industries Limited ....................................................................................................................................... 16
    Sanochemia Pharmazeutika AG.................................................................................................................................................. 17
Muscle Spasm – Therapeutics Assessment ..................................................................................................................................... 18
    Assessment by Monotherapy Products ....................................................................................................................................... 18
    Assessment by Combination Products ........................................................................................................................................ 19
    Assessment by Route of Administration ...................................................................................................................................... 20
    Assessment by Molecule Type .................................................................................................................................................... 22
Drug Profiles..................................................................................................................................................................................... 24
    Tolperisone - Drug Profile ............................................................................................................................................................ 24
         Product Description................................................................................................................................................................. 24
         Mechanism of Action ............................................................................................................................................................... 24
         R&D Progress ......................................................................................................................................................................... 24
    Baclofen GRS - Drug Profile ........................................................................................................................................................ 25
         Product Description................................................................................................................................................................. 25
         Mechanism of Action ............................................................................................................................................................... 25
         R&D Progress ......................................................................................................................................................................... 25
    SUN 09 - Drug Profile .................................................................................................................................................................. 26
         Product Description...............................
								
To top